162 related articles for article (PubMed ID: 33369269)
1. Anti-epithelial cell adhesion molecule RNA aptamer-conjugated liposomal doxorubicin as an efficient targeted therapy in mice bearing colon carcinoma tumor model.
Mashreghi M; Zamani P; Karimi M; Mehrabian A; Arabsalmani M; Zarqi J; Moosavian SA; Jaafari MR
Biotechnol Prog; 2021 May; 37(3):e3116. PubMed ID: 33369269
[TBL] [Abstract][Full Text] [Related]
2. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
Moosavian SA; Abnous K; Badiee A; Jaafari MR
Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
[TBL] [Abstract][Full Text] [Related]
3. Epithelial cell adhesion molecule aptamer conjugated PEG-PLGA nanopolymersomes for targeted delivery of doxorubicin to human breast adenocarcinoma cell line in vitro.
Alibolandi M; Ramezani M; Sadeghi F; Abnous K; Hadizadeh F
Int J Pharm; 2015 Feb; 479(1):241-51. PubMed ID: 25529433
[TBL] [Abstract][Full Text] [Related]
4. Aptamer-drug conjugate: targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity.
Dou XQ; Wang H; Zhang J; Wang F; Xu GL; Xu CC; Xu HH; Xiang SS; Fu J; Song HF
Int J Nanomedicine; 2018; 13():763-776. PubMed ID: 29440899
[TBL] [Abstract][Full Text] [Related]
5. Anti-Epcam Aptamer (Syl3c)-Functionalized Liposome for Targeted Delivery Of Doxorubicin: In Vitro And In Vivo Antitumor Studies in Mice Bearing C26 Colon Carcinoma.
Mashreghi M; Zamani P; Moosavian SA; Jaafari MR
Nanoscale Res Lett; 2020 May; 15(1):101. PubMed ID: 32383027
[TBL] [Abstract][Full Text] [Related]
6. Hybrid silica-coated Gd-Zn-Cu-In-S/ZnS bimodal quantum dots as an epithelial cell adhesion molecule targeted drug delivery and imaging system.
Akbarzadeh M; Babaei M; Abnous K; Taghdisi SM; Peivandi MT; Ramezani M; Alibolandi M
Int J Pharm; 2019 Oct; 570():118645. PubMed ID: 31465835
[TBL] [Abstract][Full Text] [Related]
7. EpCAM aptamer-functionalized mesoporous silica nanoparticles for efficient colon cancer cell-targeted drug delivery.
Xie X; Li F; Zhang H; Lu Y; Lian S; Lin H; Gao Y; Jia L
Eur J Pharm Sci; 2016 Feb; 83():28-35. PubMed ID: 26690044
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo evaluation of therapy targeting epithelial-cell adhesion-molecule aptamers for non-small cell lung cancer.
Alibolandi M; Ramezani M; Abnous K; Sadeghi F; Atyabi F; Asouri M; Ahmadi AA; Hadizadeh F
J Control Release; 2015 Jul; 209():88-100. PubMed ID: 25912964
[TBL] [Abstract][Full Text] [Related]
9. Target-specific delivery of doxorubicin to retinoblastoma using epithelial cell adhesion molecule aptamer.
Subramanian N; Raghunathan V; Kanwar JR; Kanwar RK; Elchuri SV; Khetan V; Krishnakumar S
Mol Vis; 2012; 18():2783-95. PubMed ID: 23213278
[TBL] [Abstract][Full Text] [Related]
10. Liposomal formulation of Galbanic acid improved therapeutic efficacy of pegylated liposomal Doxorubicin in mouse colon carcinoma.
Nik ME; Malaekeh-Nikouei B; Amin M; Hatamipour M; Teymouri M; Sadeghnia HR; Iranshahi M; Jaafari MR
Sci Rep; 2019 Jul; 9(1):9527. PubMed ID: 31267009
[TBL] [Abstract][Full Text] [Related]
11. Investigation of Hexadecylphosphocholine (miltefosine) usage in Pegylated liposomal doxorubicin as a synergistic ingredient: In vitro and in vivo evaluation in mice bearing C26 colon carcinoma and B16F0 melanoma.
Teymouri M; Farzaneh H; Badiee A; Golmohammadzadeh S; Sadri K; Jaafari MR
Eur J Pharm Sci; 2015 Dec; 80():66-73. PubMed ID: 26299343
[TBL] [Abstract][Full Text] [Related]
12. EGFR Targeting of Liposomal Doxorubicin Improves Recognition and Suppression of Non-Small Cell Lung Cancer.
Moles E; Chang DW; Mansfeld FM; Duly A; Kimpton K; Logan A; Howard CB; Thurecht KJ; Kavallaris M
Int J Nanomedicine; 2024; 19():3623-3639. PubMed ID: 38660023
[TBL] [Abstract][Full Text] [Related]
13. Preparation and characterization of PEGylated liposomal Doxorubicin targeted with leptin-derived peptide and evaluation of their anti-tumor effects, in vitro and in vivo in mice bearing C26 colon carcinoma.
Shahraki N; Mehrabian A; Amiri-Darban S; Moosavian SA; Jaafari MR
Colloids Surf B Biointerfaces; 2021 Apr; 200():111589. PubMed ID: 33545570
[TBL] [Abstract][Full Text] [Related]
14. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.
Zahmatkeshan M; Gheybi F; Rezayat SM; Jaafari MR
Eur J Pharm Sci; 2016 Apr; 86():125-35. PubMed ID: 26972276
[TBL] [Abstract][Full Text] [Related]
15. RNA aptamer-conjugated liposome as an efficient anticancer drug delivery vehicle targeting cancer cells in vivo.
Baek SE; Lee KH; Park YS; Oh DK; Oh S; Kim KS; Kim DE
J Control Release; 2014 Dec; 196():234-42. PubMed ID: 25450401
[TBL] [Abstract][Full Text] [Related]
16. Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas.
Amin M; Badiee A; Jaafari MR
Int J Pharm; 2013 Dec; 458(2):324-33. PubMed ID: 24148663
[TBL] [Abstract][Full Text] [Related]
17. Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: An in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity.
Teymouri M; Badiee A; Golmohammadzadeh S; Sadri K; Akhtari J; Mellat M; Nikpoor AR; Jaafari MR
Int J Pharm; 2016 Sep; 511(1):236-244. PubMed ID: 27363937
[TBL] [Abstract][Full Text] [Related]
18. Aptamer-conjugated and doxorubicin-loaded unimolecular micelles for targeted therapy of prostate cancer.
Xu W; Siddiqui IA; Nihal M; Pilla S; Rosenthal K; Mukhtar H; Gong S
Biomaterials; 2013 Jul; 34(21):5244-53. PubMed ID: 23582862
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of combinatorial Janus nanoparticles based on EpCAM-PEG/PCL for targeted therapy of human colorectal adenocarcinoma.
Khezrian S; Khoee S; Caceres M
J Biomed Mater Res A; 2020 Nov; 108(11):2291-2304. PubMed ID: 32363740
[TBL] [Abstract][Full Text] [Related]
20. Antennapedia-derived positively-charged peptide faces multiple problems upon their usage as targeting ligand for liposomal doxorubicin.
Kousani S; Karimi M; Teymouri M; Navashenaq JG; Darban SA; Jaafari MR
Biotechnol Prog; 2021 Nov; 37(6):e3202. PubMed ID: 34405574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
